Solid Biosciences SLDB 深 滬
等待開盤 12-25 09:30:00 美东时间
5.90
0.000
0.00%
華盛通- 最 高6.07
- 今 開5.83
- 成交量 28.26万股
- 最 低 5.83
- 昨 收 5.90
- 總市值 4.59亿
- 52周最高 7.37
- 市盈率 靜 --
- 換手率 0.36%
- 52周最低 2.41
- 委 比 -87.06%
- 總股本 7786.91万
- 歷史最高 822.60
- 量 比 0.24
- 振 幅 4.07%
- 歷史最低 1.81
- 每 手 1
- 風險率 1.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多2026美股生物科技板块怎么投资？杰富瑞：关注这6大首选股、7大潜力标的和5大并购目标
杰富瑞近日发布了关于2026年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
12-24 17:33
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
Solid Biosciences Inc. announced that Duchenne muscular dystrophy (Duchenne) has been added to the U.S. Department of Health and Human Services' Recommended Uniform Screening Panel (RUSP),推荐作为新生儿筛查项目。Solid Biosciences是推动杜兴氏肌肉营养不良症新生儿筛查的重要支持者，预计这一举措将加速早期诊断，改善患者预后。公司正在开发的SGT-003基因疗法具有独特设计，可改善肌肉血流并减少肌肉分解，有望成为同类最佳治疗方案。
12-16 21:51
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
Solid Biosciences Inc. announced it will present data on its next-generation AAV-SLB101 capsid and cardiac gene therapy pipeline at the Global CardioVascular Clinical Trialists Forum. Dr. Gabriel Brooks, the company’s Chief Medical Officer, will deliver two presentations, lead a panel discussion, and exhibit a poster. Dr. Nicolas Christoforou, Head of Discovery and Translational Development, will also present on preclinical research for CPVT gene...
12-08 13:00
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
12-05 08:35
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. granted 23,284 restricted stock units (RSUs) to two newly hired employees. The RSUs vest annually over four years, contingent on continued employment. The grant was made under the Company’s 2024 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). Solid Biosciences focuses on developing precision genetic medicines for rare neuromuscular and cardiac diseases, with a diverse pipeline of gene the...
12-01 21:05
Solid Biosciences Announces The FDA Grants Rare Pediatric Disease Designation For SGT-212, Its Investigational Gene Therapy For Friedreich's Ataxia
Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it received Rare Pediatric
12-01 21:02
Solid Biosciences Announces Non-Exclusive Worldwide License And Collaboration Agreement With Andelyn For Use Of Solid's Proprietary, Next-Gen Capsid, AAV-SLB101
- Non-exclusive license providing Solid's proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) --
11-17 21:13
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc. announced its participation in two upcoming investor conferences. Bo Cumbo, President and CEO, and Gabriel Brooks, MD, Chief Medical Officer, will participate in fireside chats at the Jefferies Global Healthcare Conference in London on November 18, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. Live webcasts and replays will be available on the Company’s website.
11-11 13:00
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
